Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Rubinstein MM, Goss C, Avecilla ST, Dubé GP, Riely GJ, Mones JV. Management of thymoma-associated pure red cell aplasia: A novel use of blood substitute HBOC-201 in a Jehovah's Witness. Clin Case Rep. 2020;8(2):289-292.

Galassi TV, Antman-Passig M, Yaari Z, Jessurun J, Schwartz RE, Heller DA. Long-term in vivo biocompatibility of single-walled carbon nanotubes. PLoS One. 2020;15(5):e0226791.

Stopsack KH, Gerke T, Zareba P, Pettersson A, Chowdhury D, Ebot EM, et al. Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer. Carcinogenesis. 2020;41(7):904-908.

Shanmugakani RK, Srinivasan B, Glesby MJ, Westblade LF, Cárdenas WB, Raj T, et al. Current state of the art in rapid diagnostics for antimicrobial resistance. Lab Chip. 2020;20(15):2607-2625.

Allott EH, Ebot EM, Stopsack KH, Gonzalez-Feliciano AG, Markt SC, Wilson KM, et al. Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clin Cancer Res. 2020;26(5):1086-1093.

Izzo F, Lee SC, Poran A, Chaligne R, Gaiti F, Gross B, et al. DNA methylation disruption reshapes the hematopoietic differentiation landscape. Nat Genet. 2020;52(4):378-387.

Liang H, Wang Q, Wang D, Zheng H, Kalvakolanu DV, Lu H, et al. Corrigendum to "RGFP966, a histone deacetylase 3 inhibitor, promotes glioma stem cell differentiation by blocking TGF-β signaling via SMAD7" [Biochem. Pharmacol. 180 (2020) 114118]. Biochem Pharmacol. 2020;182:114223.

Pine AR, Cirigliano SM, Nicholson JG, Hu Y, Linkous A, Miyaguchi K, et al. Tumor Microenvironment Is Critical for the Maintenance of Cellular States Found in Primary Glioblastomas. Cancer Discov. 2020;10(7):964-979.

Kalish JM, Tang X-, Scognamiglio T, Zhang T, Gudas LJ. Doxycycline-induced exogenous Bmi-1 expression enhances tumor formation in a murine model of oral squamous cell carcinoma. Cancer Biol Ther. 2020;21(5):400-411.

Chaekal O-, Scaradavou A, Frenet EM, Albano MS, Cushing M, Desai P, et al. Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response. Blood Adv. 2020;4(20):5146-5156.